ACTRN12609000515291进行中（未招募）3 期
Assessing the immunogenicity of pneumococcal vaccination given as sson as possible after diagnsosis to children and adolescents with leukaemia.
HMRC CCRE in Childhood and Adolescent Immunisation0 个研究点目标入组 100 人开始时间: 2009年6月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- Years 至 18 Years（—）
- 性别
- All
入选标准
- •All children receiving therapy for Leukaemia (Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic leukaemia (AML)) will potentially be eligible for inclusion. Diagnoses are confirmed histopathologically according to national and international guidelines
排除标准
- •Exclusion criteria will include those children who suffer a relapse or have a Bone Marrow Transplant. If a study subject relapses following commencement of the study they will be excluded from further participation. Patients will not be vaccinated until their blood count is satisfactory: platelets>/= 50 x109/L and neutrophils>/=500 x 106/L. Recent immunoglobulin (within last 9 months) or previous severe adverse reaction to vaccinations will also be exclusion criteria as per the Australian Immunisation guidelines.
研究者
相似试验
招募中
2 期
Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patientspaediatric malignancyCancer - Children's - BrainCancer - Children's - Leukaemia & LymphomaCancer - Children's - OtherACTRN12613000264785Te-Yu Hung100
已完成
不适用
Study of the immunogenicity of 13-valent pneumococcal conjugate vaccine in high-risk patients who were outside recommended ages for routine vaccinatiohematological malignancies and post hematopoietic stem cell transplantationsJPRN-UMIN000038760Chiba university42
进行中（未招募）
不适用
Evaluation of immunogenicity of 7-valent Pneumococcal Conjugate Vaccine (Prevenar) and Hexavalent DtPa-HBV-IPV-Hib (InfaNrix Hexa), co-administered at the same time, versus Hexavalent vaccine, used in primary immunization schedule - NDHealthy childrenMedDRA version: 6.1Level: PTClassification code 10062163EUCTR2007-003692-39-ITAZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
已完成
不适用
Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Korean Elderly PeopleCertain infectious and parasitic diseasesKCT0001963Ewha Womans University100
进行中（未招募）
不适用
Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled TrialThe primary objectives of this study are to:1.Prospectively evaluate immunological response to vaccination with the 23-valent polysaccharide vaccine (PPV23) in HIV infected patients over a one year period.2.Evaluate whether a strategy combining a prime with the 13-valent conjugate pneumococcal vaccine (PCV) followed by a boost with the PPV23 would improve immunogenicity against Streptococcus Pneumoniae Polysaccharides (SPP) in HIV-infected patients.EUCTR2011-000260-99-IEDepartment of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8150